User menu

A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.

Bibliographic reference Gerkens, Sophie ; Beguin, Claire ; Nechelput, M. ; Annemans, L. ; Peraux, B ; et. al. A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.. In: Journal of viral hepatitis, Vol. 14, no. 8, p. 523-36 (2007)
Permanent URL http://hdl.handle.net/2078.1/11037
  1. Shepherd J, Health Technol Assess, 4, 1 (2000)
  2. Van Damme P, Acta Gastroenterol Belg, 65, 78 (2002)
  3. 3F Renard, M Autier, and D Doumont . L'hepatite C en Belgique, comment ameliorer le depistage et la prevention ? Belgique: Ecole de sante Publique, Unite d'Education pour la sante, Serie de dossiers techniques CFB, Report No. 05-34, 27 pp.
  4. Delwaide J, Acta Gastroenterol Belg, 65, 233 (2002)
  5. Sullivan S. D., Jensen D. M., Bernstein D. E., Hassanein T. I., Foster G. R., Lee S. S., Cheinquer H., Craxi A., Cooksley Graham, Klaskala W., Pettit K., Patel K. K., Green J., Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C, 10.1111/j.1572-0241.2004.30286.x
  6. Annemans L, Acta Gastroenterol Belg, 67, 1 (2004)
  7. Alberti A, Hepatol Rev, 2, 19 (2005)
  8. Salomon J. A., Empirically Calibrated Model of Hepatitis C Virus Infection in the United States, 10.1093/aje/kwf100
  9. Michielsen P, Acta Gastroenterol Belg, 66, 15 (2003)
  10. Wong John B., Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis, 10.7326/0003-4819-133-9-200011070-00008
  11. Levine Robert A., Treating Histologically Mild Chronic Hepatitis C: Monotherapy, Combination Therapy, or Tincture of Time?, 10.7326/0003-4819-129-4-199808150-00010
  12. Drummond MF, Methods for the Economic Evaluation of Health Care Programmes (1997)
  13. Sonnenberg Frank A., Beck J. Robert, Markov Models in Medical Decision Making : A Practical Guide, 10.1177/0272989x9301300409
  14. Briggs Andrew, Sculpher Mark, An Introduction to Markov Modelling for Economic Evaluation : , 10.2165/00019053-199813040-00003
  15. Fried Michael W., Shiffman Mitchell L., Reddy K. Rajender, Smith Coleman, Marinos George, Gonçales Fernando L., Häussinger Dieter, Diago Moises, Carosi Giampiero, Dhumeaux Daniel, Craxi Antonio, Lin Amy, Hoffman Joseph, Yu Jian, Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, 10.1056/nejmoa020047
  16. Hadziyannis Stephanos J., Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C : A Randomized Study of Treatment Duration and Ribavirin Dose, 10.7326/0003-4819-140-5-200403020-00010
  17. Salomon Joshua A., Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population, 10.1001/jama.290.2.228
  18. Younossi Zobair M., Singer Mendel E., McHutchison John G., Shermock Kenneth M., Cost effectiveness of interferon ?2b combined with ribavirin for the treatment of chronic hepatitis C, 10.1002/hep.510300518
  19. Bennett William G., Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C, 10.7326/0003-4819-127-10-199711150-00001
  20. Sagmeister Markus, Wong John B., Mullhaupt Beat, Renner Eberhard L., A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C : , 10.1097/00042737-200105000-00004
  21. Sennfält K., Reichard O., Hultkrantz R., Wong J. B., Jonsson D., Cost-effectiveness of Interferon Alfa-2b With and Without Ribavirin as Therapy for Chronic Hepatitis C in Sweden, 10.1080/003655201750313414
  22. Siebert U, Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C, 10.1136/gut.52.3.425
  23. Kim W. Ray, Cost-Effectiveness of 6 and 12 Months of Interferon-α Therapy for Chronic Hepatitis C, 10.7326/0003-4819-127-10-199711150-00002
  24. Wong John B., Poynard Thierry, Ling Mei-Hsiu, Albrecht Janice K., Pauker Stephen G., , Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis c, 10.1111/j.1572-0241.2000.2089_1.x
  25. Jusot J.F., Cost-effectiveness analysis of strategies for hepatitis C screening in French blood recipients, 10.1093/eurpub/11.4.373
  26. Wong JB, Acta Gastroenterol Belg, 65, 110 (2002)
  27. Cleemput I, Recommandations provisoires pour les evaluations pharmacoeconomiques en Belgique (2006)
  28. Grieve R, Cost effectiveness of interferon   or peginterferon   with ribavirin for histologically mild chronic hepatitis C, 10.1136/gut.2005.064774
  29. Shepard DS, Health and Medicine, 2, 91 (1996)
  30. Blackmore C. Craig, Ramsey Scott D., Mann Frederick A., Deyo Richard A., Cervical Spine Screening with CT in Trauma Patients: A Cost-effectiveness Analysis, 10.1148/radiology.212.1.r99jl08117
  31. Roze Stéphane, Valentine William J., Evers Thomas, Palmer Andrew J., Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting, 10.1185/030079906x115531
  32. de Torres M, Ann Hepatol, 2, 5 (2003)
  33. McCabe Chris, Dixon Simon, Testing the Validity of Cost-Effectiveness Models : , 10.2165/00019053-200017050-00007
  34. Hammerschmidt Thomas, Goertz Anita, Wagenpfeil Stefan, Neiss Albrecht, Wutzler Peter, Banz Kurt, Validation of Health Economic Models: The Example of EVITA, 10.1046/j.1524-4733.2003.65241.x